Browning of perivascular adipose tissue protects against thoracic aortic aneurysm

血管周围脂肪组织褐变可预防胸主动脉瘤

基本信息

  • 批准号:
    10580855
  • 负责人:
  • 金额:
    $ 58.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-01 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Thoracic aortic aneurysm (TAA) is a life-threatening disease and has a high mortality rate if rupture occurs. Currently, apart from endovascular or open surgery repair, no drug has been demonstrated to be effective for TAA treatment. Even though some patients with TAA have evidence of a heritable aortopathy, about 75% of TAA patients have severe aortic damage without a clear genetic etiology. The scant mechanistic knowledge is limiting the development of medications for the treatment of TAA, thus highlighting a pressing need for better understanding TAA formation and progression. Aorta is naturally surrounded by perivascular adipose tissue (PVAT). Recent large-scale epidemiological studies demonstrated that PVAT was highly associated with a significantly higher adjusted risk of all-cause cardiac mortality. We and others documented that brown-like PVAT contributes to vascular homeostasis in health, while whitening of PVAT is dysfunctional and contributes to development of the vascular diseases. A causal relationship between PVAT and TAA and the underlying mechanisms remain unknown. Our preliminary studies indicate that the PVAT near the TAA lesion in patients lost brown characteristics, and that TAA formation was dramatically increased in mice that lack normal PVAT, suggesting that dysfunctional PVAT is associated with TAA. The conditioned medium from PVAT of TAA patients induced apoptosis and inflammation in human aortic smooth muscle cells, suggesting that signaling from PVAT can cause loss of vascular smooth muscle cells (VSMC) in the aorta, which may promote TAA lesion. It is unknown whether browning of PVAT could protect against TAA. PR-domain containing 16 (PRDM16) is a determinant of browning gene programs. We show that PRDM16 expression in PVAT of TAA patients is significantly reduced when compared to that in normal PVAT. PRDM16 inhibited resistin expression in PVAT. We found that nitrated conjugated linoleic acid (NO2-CLA) induced the browning of human PVAT adipocytes by mediating PRDM16 signaling. Based on these data, we hypothesize that PRDM16-mediated PVAT browning prevents TAA formation. We will determine that 1) PRDM16 in PVAT prevents and reverses TAA in mice; 2) PRDM16 inhibits TAA by regulating PVAT crosstalk with VSMC; 3) NO2-CLA prevents TAA by targeting PRDM16. Outcomes will demonstrate that a previously unrecognized process involving loss of browning features in PVAT promotes TAA formation through crosstalk to VSMC. This work will accelerate clinical translation of a nitro-fatty acid-based treatment for TAA targeting PVAT homeostasis with this new class of drugs, currently on clinical trials for other diseases.
项目摘要/摘要 胸主动脉瘤(TAA)是一种危及生命的疾病,如果发生破裂,死亡率很高。 目前,除了血管内或开放手术修复外,还没有任何药物被证明对 TAA治疗。尽管一些患有TAA的患者有证据表明存在遗传性动脉病变,但约75%的 TAA患者有严重的主动脉损伤,没有明确的遗传病因。所缺乏的机械知识是 限制治疗TAA的药物的开发,从而突出了迫切需要更好地 了解TAA的形成和发展。主动脉自然被血管周围的脂肪组织包围。 (PVAT)。最近的大规模流行病学研究表明,PVAT与一种 调整后的全原因心脏死亡风险显著增加。我们和其他人记录了像棕色一样的 PVAT有助于健康中的血管动态平衡,而PVAT的美白功能失调,并有助于 与血管疾病的发展密切相关。PVAT和TAA之间的因果关系及其潜在的 机制仍不清楚。我们的初步研究表明,患者TAA病变附近的PVAT 失去棕色特征,在缺乏正常PVAT的小鼠中TAA的形成显著增加, 提示PVAT功能障碍与TAA有关。TAA的PVAT条件培养液 患者诱导了人主动脉平滑肌细胞的凋亡和炎症,提示信号转导 PVAT可导致主动脉内血管平滑肌细胞(VSMC)的丢失,从而促进TAA 损伤。目前尚不清楚PVAT的褐变是否能保护其免受TAA侵染。PR域,包含16个 (PRDM16)是褐变基因程序的决定因素。我们发现PRDM16在TAA的PVAT中的表达 与正常PVAT相比,患者显著减少。PRDM16抑制抵抗素表达 在PVAT中。我们发现,硝化共轭亚油酸(NO2-CLA)可引起人PVAT的褐变 脂肪细胞通过介导PRDM16信号。根据这些数据,我们假设PRDM16介导的 PVAT褐变可防止TAA的形成。我们将确定1)PVAT中的PRDM16预防和逆转 2)PRDM16通过调节PVAT与VSMC的串扰来抑制TAA;3)NO2-CLA通过以下途径抑制TAA 目标是PRDM16。结果将证明,以前未被认识到的过程涉及损失 PVAT中的褐变特征通过与VSMC的串扰促进TAA的形成。这项工作将加快 以硝基脂肪酸为基础的靶向PVAT动态平衡的TAA的临床翻译 一类药物,目前正在进行其他疾病的临床试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YUQING Eugene CHEN其他文献

YUQING Eugene CHEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YUQING Eugene CHEN', 18)}}的其他基金

Nitro-Fatty Acids and Cardiovascular Disease
硝基脂肪酸与心血管疾病
  • 批准号:
    10670429
  • 财政年份:
    2022
  • 资助金额:
    $ 58.62万
  • 项目类别:
Browning of perivascular adipose tissue protects against thoracic aortic aneurysm
血管周围脂肪组织褐变可预防胸主动脉瘤
  • 批准号:
    10462357
  • 财政年份:
    2022
  • 资助金额:
    $ 58.62万
  • 项目类别:
Development of gene editing based therapy for cardiovascular diseases
开发基于基因编辑的心血管疾病疗法
  • 批准号:
    10652321
  • 财政年份:
    2021
  • 资助金额:
    $ 58.62万
  • 项目类别:
Development of gene editing based therapy for cardiovascular diseases
开发基于基因编辑的心血管疾病疗法
  • 批准号:
    10313701
  • 财政年份:
    2021
  • 资助金额:
    $ 58.62万
  • 项目类别:
Development of gene editing based therapy for cardiovascular diseases
开发基于基因编辑的心血管疾病疗法
  • 批准号:
    10441548
  • 财政年份:
    2021
  • 资助金额:
    $ 58.62万
  • 项目类别:
IDOL and dyslipidemia in cardiovascular diseases
IDOL 与心血管疾病中的血脂异常
  • 批准号:
    10221773
  • 财政年份:
    2019
  • 资助金额:
    $ 58.62万
  • 项目类别:
IDOL and dyslipidemia in cardiovascular diseases
IDOL 与心血管疾病中的血脂异常
  • 批准号:
    10451711
  • 财政年份:
    2019
  • 资助金额:
    $ 58.62万
  • 项目类别:
KLF14 and Cardiovascular Disease
KLF14 与心血管疾病
  • 批准号:
    10319617
  • 财政年份:
    2017
  • 资助金额:
    $ 58.62万
  • 项目类别:
KLF14 and Atherosclerosis
KLF14 与动脉粥样硬化
  • 批准号:
    9333689
  • 财政年份:
    2017
  • 资助金额:
    $ 58.62万
  • 项目类别:
KLF14 and Cardiovascular Disease
KLF14 与心血管疾病
  • 批准号:
    10569551
  • 财政年份:
    2017
  • 资助金额:
    $ 58.62万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 58.62万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 58.62万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.62万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.62万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 58.62万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.62万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 58.62万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 58.62万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 58.62万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.62万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了